How Many Medical Providers Have Been Charged with Felonies for Opioid Fraud in 2018
The 2018 enforcement actions represent a watershed moment in federal opioid prosecution, and the numbers reflect a government that had committed institutional resources to healthcare fraud enforcement at a scale previously reserved for drug trafficking organizations.
In July 2018, the Department of Justice announced the largest healthcare fraud enforcement action in history. The coordinated operation charged more than six hundred defendants across the country, including approximately one hundred sixty medical professionals, in connection with opioid prescribing and distribution fraud. The defendants included physicians, nurse practitioners, physician assistants, dentists, pharmacists, and other licensed providers. The charges encompassed opioid prescribing outside the usual course of professional practice, unlawful distribution of controlled substances, healthcare fraud, and money laundering arising from the proceeds of the fraudulent prescribing.
The Scale of the 2018 Action
The July 2018 enforcement action was the product of coordinated investigation across multiple federal districts, conducted through the DEA’s Tactical Diversion Squads, the FBI’s healthcare fraud units, and the OIG’s investigative staff, working under the direction of United States Attorney’s offices in more than a dozen states. The geographic scope of the action reflected the national character of the opioid crisis and the government’s determination to demonstrate enforcement reach not limited to any single region.
Among the defendants charged were physicians who had prescribed millions of opioid doses over the preceding years, some of whom had already had their DEA registrations suspended or revoked and who had continued prescribing through other means. The charges in the most significant individual cases alleged prescribing of hundreds of thousands of doses of opioids over extended periods, with loss amounts to federal healthcare programs reaching into the tens of millions of dollars.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196The Legal Theories Applied
The charges filed in the 2018 action drew on the full range of federal statutes applicable to controlled substance diversion and healthcare fraud. The primary charge in cases involving physician prescribing was 21 U.S.C. 841, drug distribution outside the usual course of professional practice, which carries the same mandatory minimum penalties as drug trafficking charges. Healthcare fraud charges under 18 U.S.C. 1347 addressed the fraudulent billing of Medicare and Medicaid for clinical encounters associated with the controlled substance prescriptions. Conspiracy charges under 18 U.S.C. 371 and 21 U.S.C. 846 reached participants in coordinated prescribing and billing schemes who might not have met every element of the substantive offense individually.
The Role of Data Analytics
The 2018 enforcement action was enabled in substantial part by advances in the DEA’s and OIG’s data analytics capabilities. The government’s ability to identify prescribing outliers across millions of claims records, to correlate prescribing patterns with PDMP data across multiple states, and to prioritize the most significant cases for prosecution from a much larger universe of anomalous prescribers reflected analytical tools developed and refined over the preceding decade.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
The 2018 enforcement action was not the end of a cycle. It was a demonstration of a capability that the government has continued to develop and apply. The practitioners who observed the 2018 announcement and who believed that the enforcement had addressed the problem were mistaken. The investigation was demonstrating what it could do. The subsequent years have reflected that demonstration at sustained and in some cases increasing levels.
Context and Lessons
The 2018 action occurred against the backdrop of a political and public health environment in which the opioid crisis had become a central concern of federal policy. Congressional appropriations for healthcare fraud enforcement, DEA diversion enforcement, and addiction treatment had increased substantially in the preceding years. For practitioners monitoring the enforcement environment, the 2018 action confirmed that the government’s opioid enforcement priority was real, sustained, and backed by the investigative resources and prosecutorial determination to produce large-scale results.